These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

178 related items for PubMed ID: 36602607

  • 1. Bone loss after denosumab discontinuation is prevented by alendronate and zoledronic acid but not risedronate: a retrospective study.
    Tutaworn T, Nieves JW, Wang Z, Levin JE, Yoo JE, Lane JM.
    Osteoporos Int; 2023 Mar; 34(3):573-584. PubMed ID: 36602607
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Comparison of the Efficacy of Zoledronate Acid or Denosumab After Switching from Romosozumab in Japanese Postmenopausal Patients.
    Oue T, Shimizu T, Asano T, Shimodan S, Ishizu H, Arita K, Iwasaki N.
    Calcif Tissue Int; 2023 Jun; 112(6):683-690. PubMed ID: 37037949
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Discontinuation of denosumab in men with prostate cancer.
    Sølling AS, Harsløf T, Brockstedt HK, Langdahl B.
    Osteoporos Int; 2023 Feb; 34(2):291-297. PubMed ID: 36402867
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. ZOLEDRONIC ACID VERSUS ALENDRONATE IN THE TREATMENT OF CHILDREN WITH OSTEOGENESIS IMPERFECTA: A 2-YEAR CLINICAL STUDY.
    Lv F, Liu Y, Xu X, Song Y, Li L, Jiang Y, Wang O, Xia W, Xing X.
    Endocr Pract; 2018 Feb; 24(2):179-188. PubMed ID: 29466057
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Regional bone metabolism at the lumbar spine and hip following discontinuation of alendronate and risedronate treatment in postmenopausal women.
    Frost ML, Siddique M, Blake GM, Moore AE, Marsden PK, Schleyer PJ, Eastell R, Fogelman I.
    Osteoporos Int; 2012 Aug; 23(8):2107-16. PubMed ID: 21983795
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. The clinical effectiveness of denosumab (Prolia®) in patients with hormone-sensitive cancer receiving endocrine therapy, compared to bisphosphonates, selective estrogen receptor modulators (SERM), and placebo: a systematic review and network meta-analysis.
    Nicolopoulos K, Moshi MR, Stringer D, Ma N, Jenal M, Vreugdenburg T.
    Arch Osteoporos; 2023 Jan 10; 18(1):18. PubMed ID: 36624318
    [Abstract] [Full Text] [Related]

  • 15. THE CLINICAL CHARACTERISTICS AND EFFICACY OF BISPHOSPHONATES IN AUDLT PATIENTS WITH OSTEOGENESIS IMPERGECTA.
    Xu XJ, Ma DD, Lv F, Wang JY, Liu Y, Xia WB, Jiang Y, Wang O, Xing XP, Yu W, Li M.
    Endocr Pract; 2016 Nov 10; 22(11):1267-1276. PubMed ID: 27482615
    [Abstract] [Full Text] [Related]

  • 16. Significant bone loss after stopping long-term denosumab treatment: a post FREEDOM study.
    Zanchetta MB, Boailchuk J, Massari F, Silveira F, Bogado C, Zanchetta JR.
    Osteoporos Int; 2018 Jan 10; 29(1):41-47. PubMed ID: 28975362
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Treatment With Zoledronate Subsequent to Denosumab in Osteoporosis: A 2-Year Randomized Study.
    Sølling AS, Harsløf T, Langdahl B.
    J Bone Miner Res; 2021 Jul 10; 36(7):1245-1254. PubMed ID: 33813753
    [Abstract] [Full Text] [Related]

  • 19. Bisphosphonates and glucocorticoid osteoporosis in men: results of a randomized controlled trial comparing zoledronic acid with risedronate.
    Sambrook PN, Roux C, Devogelaer JP, Saag K, Lau CS, Reginster JY, Bucci-Rechtweg C, Su G, Reid DM.
    Bone; 2012 Jan 10; 50(1):289-95. PubMed ID: 22061864
    [Abstract] [Full Text] [Related]

  • 20. Intravenous zoledronic acid 5 mg in the treatment of postmenopausal women with low bone density previously treated with alendronate.
    McClung M, Recker R, Miller P, Fiske D, Minkoff J, Kriegman A, Zhou W, Adera M, Davis J.
    Bone; 2007 Jul 10; 41(1):122-8. PubMed ID: 17468062
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.